SUMMARY
Thr8]-angiotensin II at a rate of 250ng/Kg/min for 30min did not affect the furosemide-induced increase in MAP and heart rate. The furosemide-induced increase in plasma NA level was also not affected by intravenous infusion of the same dose of either antagonist. These results are shown in Fig.3 .
DISCUSSION
It has been well documented that angiotensin II affects the central nervous system.1) Its central actions may be mediated through stimulation of brain vasomotor centers, because the blood pressure elevation induced by angiotensin II can be blocked by adrenergic neuron blocking agents.9) However, since angiotensin II does not freely cross the blood-brain barrier,10),11) brain sites outside the blood-brain barrier are most likely to be candidates for mediators of the action of circulating angiotensin II on the brain.
In the present study, we administered furosemide to increase plasma angiotensin II levels, and infused two angiotensin II antagonists, [Sar1, Thr8]-and [Sar1, Ile8]-angiotensin II, into a vertebral artery to examine the role of the central sympathetic activation induced by circulating angiotensin II in blood pressure regulation. In addition, the responses of arterial blood pressure and plasma NA to the antagonists were compared to test for possible differences in catecholamine release and cardiac effects.12),13) The administration of furosemide led to a significant increase in plasma NA levels and PRA. In addition, a marked increase in heart rate was observed. The influence of acute administration of furosemide on plasma NA is complex and may be affected by many factors. Decreased plasma volume, the baroreceptor reflex and increased circulating angiotensin II levels may all contribute to the furosemide-induced increase in plasma NA. We previously reported that the furosemide-induced increase in plasma NA was inhibited by a large dose of an angiotensin II antagonist, indicating a significant role of the renin-angiotensin system on increased plasma NA levels.5) However, since angiotensin II stimulates sympathetic neural activity by affecting various sites of the sympathetic nervous system, an attempt was made in this study to inhibit the central action of circulating angiotensin II by intravertebral artery infusion of an angiotensin II antagonist. The furosemideinduced increase in plasma NA was significantly suppressed by intravertebral artery infusion of [Sar1, Thr8]-as well as [Sar1, Ile8]-angiotensin II at the rate of 250ng/Kg/min, though both were ineffective when infused intravenously. In addition, infusion of these antagonists into the vertebral artery suppressed the furosemide-induced increase in heart rate. These results suggest that circulating angiotensin II may stimulate sympathetic neural activity in-directly through the central nervous system when the renin-angiotensin system is activated.
Although intravenous infusion of angiotensin II antagonists at a rate of 250ng/Kg/min did not produce a significant fall in arterial blood pressure, the central infusions resulted in a significant blood pressure fall. This is compatible with the observation of Sweet et al that the hypertensive response to angiotensin II infused into the vertebral artery is completely antagonized by concomitant infusion of [Sar1, Ile8]-angiotensin II.14) The fall in blood pressure induced by [Sar1, Thr8]-angiotensin II was greater than that by [Sar1, Ile8]-angiotensin II. In addition, the suppression of heart rate by [Sar1, Thr8]-angiotensin II seemed to be more pronounced than that by [Sar1, Ile8]-angioterisin II. Since angiotensin II can inhibit vagal tone,15) any antagonist will apparently increase vagal tone in conditions when the angiotensin II level is high. Bravo et al have shown in salt-deprived dogs that intravenous infusion of [Sar1, Thr5]-angiotensin II reduces blood pressure, cardiac output and heart rate; these decreases are reversed by atropine.16) This observation gives a basis for an influence that the marked decrease in MAP or heart rate induced by [Sar1, Thr8]-angiotensin II may be due, in part, to the overactivity of the parasympathetic nervous system.
